New daily pill could help breast cancer patients who Can't tolerate standard hormone drugs
NCT ID NCT07541079
First seen Apr 30, 2026 · Last updated Jun 19, 2026 · Updated 8 times
Summary
This phase 3 trial is testing a daily pill called giredestrant in 300 people with early-stage, hormone-sensitive breast cancer who had side effects from standard aromatase inhibitors. The study will track how well patients stick with the treatment, any side effects, and changes in symptoms like joint pain and hot flashes. Participants will take the drug for up to 4.5 years or until their cancer returns or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
giredestrant (a daily oral drug)
What this could lead to
If it works, this could offer a well-tolerated daily pill for people with early breast cancer who cannot take standard hormone therapy.
What could go wrong
This is a single-arm, open-label study with no placebo or comparison group, so results may be less reliable. Side effects or lack of benefit could still lead to stopping treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.